While therapeutic targeting of the PI3K/Akt/mTOR signaling cascade at multiple molecular levels has been shown preclinically to provide better antitumor effects than selective inhibition of only individual components of this pathway, a priori identification of leukemias likely to respond has so far proven elusive. The gene discussed is PIK3CD; the disease is leukemia.